167 related articles for article (PubMed ID: 28336942)
1. Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model.
Tokunaga Y; Osawa Y; Ohtsuki T; Hayashi Y; Yamaji K; Yamane D; Hara M; Munekata K; Tsukiyama-Kohara K; Hishima T; Kojima S; Kimura K; Kohara M
Sci Rep; 2017 Mar; 7(1):325. PubMed ID: 28336942
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
Kimura K; Ikoma A; Shibakawa M; Shimoda S; Harada K; Saio M; Imamura J; Osawa Y; Kimura M; Nishikawa K; Okusaka T; Morita S; Inoue K; Kanto T; Todaka K; Nakanishi Y; Kohara M; Mizokami M
EBioMedicine; 2017 Sep; 23():79-87. PubMed ID: 28844410
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice.
Osawa Y; Oboki K; Imamura J; Kojika E; Hayashi Y; Hishima T; Saibara T; Shibasaki F; Kohara M; Kimura K
EBioMedicine; 2015 Nov; 2(11):1751-8. PubMed ID: 26870800
[TBL] [Abstract][Full Text] [Related]
4. The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice.
Okazaki H; Sato S; Koyama K; Morizumi S; Abe S; Azuma M; Chen Y; Goto H; Aono Y; Ogawa H; Kagawa K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Kouji H; Nishioka Y
Exp Lung Res; 2019 Sep; 45(7):188-199. PubMed ID: 31298961
[No Abstract] [Full Text] [Related]
5. Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12.
Akcora BÖ; Storm G; Bansal R
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):804-818. PubMed ID: 29217140
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura K; Kanto T; Shimoda S; Harada K; Kimura M; Nishikawa K; Imamura J; Ogawa E; Saio M; Ikura Y; Okusaka T; Inoue K; Ishikawa T; Ieiri I; Kishimoto J; Todaka K; Kamisawa T
EBioMedicine; 2022 Jun; 80():104069. PubMed ID: 35605429
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M; Nishikawa K; Osawa Y; Imamura J; Yamaji K; Harada K; Yatsuhashi H; Murata K; Miura K; Tanaka A; Kanto T; Kohara M; Kamisawa T; Kimura K
Hepatol Commun; 2022 Oct; 6(10):2732-2747. PubMed ID: 35855613
[TBL] [Abstract][Full Text] [Related]
8. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
Nishikawa K; Osawa Y; Kimura K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308992
[TBL] [Abstract][Full Text] [Related]
9. Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl
Sun H; Chen G; Wen B; Sun J; An H; Pang J; Xu W; Yang X; He S
J Pharmacol Sci; 2018 Mar; 136(3):133-141. PubMed ID: 29501581
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder.
Yamaji K; Iwabuchi S; Tokunaga Y; Hashimoto S; Yamane D; Toyama S; Kono R; Kitab B; Tsukiyama-Kohara K; Osawa Y; Hayashi Y; Hishima T; Tateno C; Kimura K; Okanoue T; Kohara M
Biomed Pharmacother; 2023 Oct; 166():115379. PubMed ID: 37647690
[TBL] [Abstract][Full Text] [Related]
11. Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis.
Yoshida M; Matsuzaki J; Fujita K; Kimura M; Umezu T; Tokuda N; Yamaguchi T; Kuroda M; Ochiya T; Saito Y; Kimura K
Sci Rep; 2024 Mar; 14(1):6266. PubMed ID: 38491114
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis.
Henderson WR; Chi EY; Ye X; Nguyen C; Tien YT; Zhou B; Borok Z; Knight DA; Kahn M
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14309-14. PubMed ID: 20660310
[TBL] [Abstract][Full Text] [Related]
13. Prevention of urethral fibrosis induced by transforming growth factor beta 1 using selective Wnt/β-catenin signaling inhibitors in a rat model.
Choi KH; Kim DK; Kim AR; Lee SR
Int J Urol; 2022 Jul; 29(7):764-771. PubMed ID: 35381618
[TBL] [Abstract][Full Text] [Related]
14. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
15. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
[TBL] [Abstract][Full Text] [Related]
16. Wnt/β-catenin signaling inhibitor ICG-001 enhances pigmentation of cultured melanoma cells.
Kim KI; Jeong DS; Jung EC; Lee JH; Kim CD; Yoon TJ
J Dermatol Sci; 2016 Nov; 84(2):160-168. PubMed ID: 27567978
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the canonical Wnt signaling pathway by a β-catenin/CBP inhibitor prevents heart failure by ameliorating cardiac hypertrophy and fibrosis.
Methatham T; Tomida S; Kimura N; Imai Y; Aizawa K
Sci Rep; 2021 Jul; 11(1):14886. PubMed ID: 34290289
[TBL] [Abstract][Full Text] [Related]
19. Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy.
Chen L; Chen DQ; Wang M; Liu D; Chen H; Dou F; Vaziri ND; Zhao YY
Chem Biol Interact; 2017 Aug; 273():56-72. PubMed ID: 28578904
[TBL] [Abstract][Full Text] [Related]
20. Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells.
Chida T; Ito M; Nakashima K; Kanegae Y; Aoshima T; Takabayashi S; Kawata K; Nakagawa Y; Yamamoto M; Shimano H; Matsuura T; Kobayashi Y; Suda T; Suzuki T
Hepatology; 2017 Nov; 66(5):1430-1443. PubMed ID: 28621467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
